Multiplex Deletion of Myeloid Antigens CD33 and CLL-1 by CRISPR/Cas9 in Human Hematopoietic Stem Cells Highlights the Potential of Next-Generation Transplantation for AML Treatment
Publications
Filter by:
Clear all filters
Search Publications
A Novel Scalable Electroporation Platform for the Manufacturing of Gene Modified Hematopoietic Stem and Progenitor Cell Therapies
Novel Automated, Functionally Closed System for Rapid Immunomagnetic Negative Selection of T Cells
Multiplex Editing of Hematopoietic Stem and Progenitor Cells (HSPCs) with CRISPR Cas Nucleases Achieves High On Target Editing with Undetectable Translocations
Multiplex Base Editing in Human Hematopoietic Stem and Progenitor Cells (HSPCs) Enables Efficient Removal of Multiple Surface Antigens in Acute Myeloid Leukemia (AML) Immunotherapy
G-CSF/Plerixafor Dual-Mobilized Donor Derived CD33CAR T-Cells as Potent and Effective AML Therapy in Pre-Clinical Models
Multiplex Engineering of Human CD34+ HSPCs Enables Dual Gene Knockout While Maintaining High Engraftment Potential and Safety
Knock Out of CD123 or CLL-1 by CRISPR-Cas9 Editing From Human Hematopoietic Stem Cell Transplantations Provide New Possibilities for Increasing Therapeutic Index and Safety for AML Treatment
An NFAT Promoter–Based Fluorescent Jurkat Cell Platform for High- Throughput Screening of Chimeric Antigen Receptor (CAR) Constructs